IndicationProjectPhaseEstimated
submission
Estimated
launch
SPECIALTY PHARMA
ADHD—adolescentDAYTRANA (US)Registration 2010
ADHDVYVANSE (EU)320112012
ADHD—for use in combination with
other ADHD treatments
INTUNIV (US)320102011
Ulcerative colitis—maintenance of
remission treatment
LIALDA (US)320102011
DiverticulitisLIALDA/MEZAVANT320122013
Chronic Kidney diseaseFOSRENOL (US)Pre-registration  
Prevention and reduction of scarringJUVISTA (EU)3 2013–2016
Adjunctive therapy in depressionVYVANSE2  
Cognitive impairment in depressionVYVANSE2  
Negative symptoms and
cognitive impairment in
schizophrenia
VYVANSE2  
Arteriovenous grafts in
hemodialysis patients
SPD 5351 2013–2016
 
HUMAN GENETIC THERAPIES
Gaucher disease Type 1VPRIV (EU)RegistrationH2–20092010
Fabry diseaseREPLAGAL (US)Registration 2010
Hereditary angioedemaFIRAZYR (US)3 2011
Hunter syndrome CNSHGT1/2 2013–2016
Metachromatic Leukodystrophy ('MLD') HGT 1110Pre-clinical 2013–2016
Sanfilippo A syndrome HGT 1410Pre-clinical 2013–2016
Globoid Cell Leukodystrophy ('GLD', Krabbe) HGT 2610Pre-clinical 2013–2016
Santaris collaboration3 targetsPre-clinical 2013–2016